Charlien Berghen

Dr. Charlien Berghen

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in European Urology Oncology
Verified
Journal Article
Closed access
CBCharlien Berghen
Charlien Berghen
Steven JoniauSteven Joniau
Steven Joniau
POPiet Ost
Piet Ost
KPKenneth Poels
Kenneth Poels
WEWouter Everaerts
Wouter Everaerts
GMGert De Meerleer
Gert De Meerleer

21 November 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
HEHans Van der Eecken
Hans Van der Eecken
Steven JoniauSteven Joniau
Steven Joniau
CBCharlien Berghen
Charlien Berghen
KRKato Rans
Kato Rans
GMGert O. De Meerleer
Gert O. De Meerleer
A possible link between diet and cancer has long been considered, with growing interest in phytochemicals. Soy isoflavones have been associated with a reduced risk of prostate cancer in Asian populations. Of the soy isoflavones, genistein and daidzein, in particular, have been studied, but recently, equol as a derivative has gained interest because it is more biologically potent. Different mechanisms of action have already been studied for the different isoflavones in multiple conditions, such as breast, gastrointestinal, and urogenital cancers. Many of these mechanisms of action could also be demonstrated in the prostate, both in vitro and in vivo. This review focuses on the known mechanisms of action at the cellular level and compares them between genistein, daidzein, and equol. These include androgen- and estrogen-mediated pathways, regulation of the cell cycle and cell proliferation, apoptosis, angiogenesis, and metastasis. In addition, antioxidant and anti-inflammatory effects and epigenetics are addressed.

13 August 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GDGaëtan Devos
Gaëtan Devos
CBCharlien Berghen
Charlien Berghen
HEHenri Van Eecke
Henri Van Eecke
ASArthur Vander Stichele
Arthur Vander Stichele
HPHendrik Paul Van Poppel
Hendrik Paul Van Poppel
Steven JoniauSteven Joniau
Steven Joniau
Several retrospective and a few prospective studies have shown that metastasis-directed therapy (MDT) could delay clinical progression and postpone the initiation of systemic treatment in oligorecurrent prostate cancer (PCa) patients. However, these endpoints are strongly influenced by variables such as concomitant use of androgen deprivation therapy (ADT) and follow-up imaging protocols. The aim of this manuscript was to assess palliative ADT- and metastatic castration-resistant prostate cancer (mCRPC)-free survival as long-term oncological outcomes in oligorecurrent PCa treated by MDT. We retrospectively identified consecutive post-prostatectomy oligorecurrent PCa patients treated by MDT (salvage lymphadenectomy, radiotherapy, or metastasectomy) at our tertiary referral center. Patients were eligible for inclusion if they developed recurrence following radical prostatectomy, had ≤5 metastatic lesions on imaging and had a serum testosterone >50 ng/dL or a testosterone suppression therapy-free interval of >2 years prior to the first MDT as an assumption of recovered serum testosterone (if no testosterone measurement available). Patients with castration-resistant or synchronous oligometastatic PCa at the time of first MDT were excluded. Repeated MDTs were allowed, as well as a period of concomitant ADT. Kaplan–Meier analyses were performed to assess palliative ADT-free and mCRPC-free survival. We identified 191 eligible patients who underwent MDT. Median follow-up from first MDT until last follow-up or death was 45 months (IQR 27–70; mean 51 months). Estimated median palliative-ADT free survival was 66 months (95% CI 58–164) and estimated median mCRPC-free survival was not reached (mean 117 months, 95% CI 103–132). In total, 314 MDTs were performed and 25 patients (13%) received ≥3 MDTs. This study demonstrated that (repeated) MDT is feasible and holds promise in terms of palliative ADT-free and mCRPC-free survival for patients with oligorecurrent PCa. However, these findings should be confirmed in prospective randomized controlled trials.

13 December 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
CDCédric Draulans
Cédric Draulans
Steven JoniauSteven Joniau
Steven Joniau
VFValérie Fonteyne
Valérie Fonteyne
LDLouke Delrue
Louke Delrue
KDKarel Decaestecker
Karel Decaestecker
GMGert O. De Meerleer
Gert O. De Meerleer
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: In prostate cancer with histopathological proven pelvic lymph node metastasis (pN1) after extended pelvic lymph node dissection, multimodality treatment consisting of treatment of the primary tumour and whole pelvic radiotherapy combined with androgen deprivation therapy (ADT) offers promising results and results in better cause-specific survival rates compared to ADT alone. However, in case more than one pelvic lymph node is invaded by tumour, approximately 40% of the patients relapse biochemically and clinically. Clinical relapse is present in the para-aortic lymph nodes (M1a disease) in up to 77% of the relapsing cases. Objective: We hypothesize that, based on the evidence that positive lymph nodes represent the door to haematogenous dissemination, elective para-aortic irradiation will reduce the development of both retroperitoneal nodal (M1a) and distant metastasis (M1b/M1c disease), postpone the need for palliative androgen deprivation therapy and prolong the time to castration-refractory disease. Methods: To test this hypothesis, we will conduct a prospective non-randomized phase 2 trial that will study the efficacy of additional elective para-aortic radiation therapy in pN1 patients compared to those who were historically treated with adjuvant whole pelvic radiotherapy alone. We aim to include 137 patients with prostate cancer and presence of pN1 disease after extended pelvic lymph node dissection. With this number of patients, an improvement in clinical relapse free survival (cRFS) at 5 years by 15% can be detected with a power of 80%. Results: Recruitment of patients for this trial started in 2017. The approximate date when recruitment will be completed is March 2020. Conclusions: This is the first phase II trial to investigate the benefit of an elective para-aortic radiotherapy in prostate cancer patients. The result of this trial can potentially serve as a sound base for a later randomized phase III trial. All participants are given a PART information sheet and required to give written informed consent. Results will be expected to be published in a peer-reviewed journal. Clinical Trial: This study is registered at ClinicalTrials.gov, NCT03079323 (March 14, 2017).

24 May 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CBCharlien Berghen
Charlien Berghen
SJSteven Joniau
Steven Joniau
KRKato Rans
Kato Rans
GDGaëtan Devos
Gaëtan Devos
KPKenneth Poels
Kenneth Poels
GMGert De Meerleer
Gert De Meerleer
Background: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressive lesions while other metastases are still controlled by ongoing systemic treatment. Methods: In this single arm prospective phase II trial, we aim to include 18 patients with oligoprogressive mCRPC (1–3 metastases and/or local recurrence) who will be treated with metastasis-directed therapy to all visible progressive lesions. Progression is based on conventional imaging, as the use of PSMA PET-CT is considered investigational. However all patients will undergo PSMA PET-CT and the images will be blinded until progression. Primary endpoint is the postponement of the start of next-line systemic treatment (NEST) and the additional clinical value of PSMA PET-CT. Recruitment of patients for this trial started in January 2020 and will be completed approximately by December 2020. Discussion: In this phase 2 trial on oligoprogressive mCRPC, we will investigate the benefit of progression-directed therapy while continuing ongoing systemic treatment. We hypothesize that progression-directed therapy (PDT) with surgery or stereotactic body radiation therapy for these oligoprogressive lesions will postpone the start of next-line systemic treatment and therefore serve as a new or add-on therapy in the spectrum of treatments available for mCRPC. The results of this trial will serve as guidance for a later randomized phase 3 trial. All participants are given an information sheet and are required to give written informed consent. Results will be published in a peer-reviewed journal. Trial registration: This study is registered at ClinicalTrials.gov: NCT04222634 (December 18th 2019).

7 May 2020 in ecancermedicalscience
Verified
Journal Article
Open access
CBCharlien Berghen
Charlien Berghen
SJSteven Joniau
Steven Joniau
CVChristof Vulsteke
Christof Vulsteke
MAMaarten Albersen
Maarten Albersen
GDGaëtan Devos
Gaëtan Devos
GMGert De Meerleer
Gert De Meerleer
Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news Charlien Berghen1, Steven Joniau2, Christof Vulsteke3